Lixte Biotechnology Holdings, Inc.
LIXT
$4.20
$0.143.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.36% | -25.91% | -32.25% | -32.10% | -30.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.23% | -23.54% | -29.32% | -29.81% | -30.04% |
| Operating Income | 2.23% | 23.54% | 29.32% | 29.81% | 30.04% |
| Income Before Tax | -2.07% | 23.41% | 29.13% | 29.51% | 29.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.07% | 23.41% | 29.13% | 29.51% | 29.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.07% | 23.41% | 29.13% | 29.51% | 29.65% |
| EBIT | 2.23% | 23.54% | 29.32% | 29.81% | 30.04% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 33.86% | 29.79% | 39.16% | 42.49% | 46.02% |
| Normalized Basic EPS | 34.32% | 29.80% | 39.16% | 42.49% | 46.01% |
| EPS Diluted | 33.86% | 29.79% | 39.16% | 42.49% | 46.02% |
| Normalized Diluted EPS | 34.32% | 29.80% | 39.16% | 42.49% | 46.01% |
| Average Basic Shares Outstanding | 51.23% | 9.79% | 11.84% | 17.47% | 27.28% |
| Average Diluted Shares Outstanding | 51.23% | 9.79% | 11.84% | 17.47% | 27.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |